China’s Image-Guided Radiation Therapy Market, estimated at US$ XX billion in 2024 and 2025, is projected to grow steadily at a CAGR of XX% from 2025 to 2030, ultimately reaching US$ XX billion by 2030.
The global image-guided radiation therapy market was valued at $1.8 billion in 2022, increased to $1.9 billion in 2023, and is expected to reach $2.4 billion by 2028, growing at a robust 5.2% CAGR.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171554723
Drivers
The China Image-Guided Radiation Therapy (IGRT) Market is primarily driven by the escalating incidence and prevalence of various cancers across the large population base. As the number of cancer cases rises, there is a commensurate surge in demand for highly precise and non-invasive treatment modalities like IGRT, which minimizes damage to surrounding healthy tissue. This demand is further amplified by the strong governmental commitment to modernizing the national healthcare infrastructure, as evidenced by significant investments aimed at expanding cancer care capabilities and increasing the availability of advanced radiotherapy equipment, such as sophisticated Linear Accelerators (Linacs) capable of IGRT. Furthermore, the push towards personalized and precision medicine in oncology requires tools that can ensure high treatment accuracy by visualizing the tumor target immediately before and during treatment. The continuous technological advancements in imaging modalities—such as cone-beam computed tomography (CBCT), MRI-guided systems, and surface tracking—integrated into radiotherapy equipment enhance the efficacy and safety of cancer treatment, solidifying IGRT’s position as a critical component in modern Chinese oncology care. The growing awareness and adoption of these advanced techniques by specialized cancer centers and hospitals further fuel market growth, supported by favorable regulatory policies that encourage the deployment of high-end medical devices.
Restraints
Despite the strong drivers, the China IGRT Market faces notable restraints that temper its growth rate. A primary challenge is the high capital cost associated with acquiring, installing, and maintaining advanced IGRT equipment. Sophisticated Linacs and ancillary imaging systems require substantial upfront investment, which can be prohibitive for many provincial and smaller hospitals, limiting their widespread adoption across the country. Furthermore, a significant restraint is the severe shortage of highly skilled healthcare professionals, including specialized radiation oncologists, medical physicists, and radiotherapy technologists, who are trained to operate and effectively plan treatments using complex IGRT technologies. This dearth of expertise restricts the optimal utilization of the installed base and hinders the quality of treatment delivery, especially in less-developed regions. The complexity of integrating IGRT systems with existing hospital information systems and oncology workflows presents technical and logistical hurdles. While some domestic innovation is occurring, China still faces a gap in innovation, lagging behind global leaders in terms of targets in clinical trials, which may deter new international market entrants and limit the rapid uptake of cutting-edge IGRT techniques.
Opportunities
Significant opportunities exist within the China IGRT Market, largely stemming from the national shift toward value-based healthcare and continuous technological refinement. The rising healthcare expenditure across developing provinces presents a substantial opportunity for vendors to expand their market reach beyond the tier-one cities, catering to the increasing demand for advanced cancer care in previously underserved areas. A major avenue for growth is the integration of IGRT platforms with Artificial Intelligence (AI) and machine learning, which can optimize treatment planning, automate image registration, and predict treatment outcomes, thereby increasing efficiency and precision. Furthermore, the growing focus on ultra-hypofractionation and Stereotactic Body Radiation Therapy (SBRT), where IGRT is indispensable for verifying tumor position before each fraction, offers a high-growth segment. The market can also capitalize on the expansion of key domestic and international players into emerging economies within China, coupled with the development of more affordable and locally manufactured IGRT components and software. Promoting public and professional education on the clinical benefits of IGRT remains a powerful opportunity to accelerate market acceptance and drive broader clinical adoption.
Challenges
The key challenges confronting the China IGRT Market are primarily centered on achieving widespread accessibility, balancing technological adoption with regulatory compliance, and managing competition from alternative technologies. The regulatory approval process for novel high-end medical devices like IGRT systems can be stringent and lengthy, often complicating the rapid commercialization and clinical use of the latest global innovations. Ensuring data integrity and standardization across diverse clinical settings in China remains a persistent challenge, essential for effective treatment planning and large-scale clinical trials. Moreover, the availability of alternative, sometimes less expensive, radiation therapy techniques and the rise of particle therapy equipment pose competitive challenges to IGRT’s dominance. Overcoming the technical complexities related to system robustness and ensuring long-term operational reliability in high-throughput Chinese hospitals requires continuous investment in maintenance and service infrastructure. Finally, while government support is strong, the challenge lies in effectively allocating resources to address the uneven distribution of IGRT capabilities between top-tier urban centers and remote hospitals.
Role of AI
Artificial Intelligence (AI) is poised to fundamentally transform the China IGRT Market by substantially enhancing the precision, speed, and efficiency of radiation therapy workflows. AI algorithms are crucial for automating and optimizing key steps in the IGRT process, starting with multi-modal image fusion and segmentation of organs-at-risk and target volumes, significantly reducing the time required for treatment planning. During treatment delivery, AI-powered real-time motion tracking and image analysis allow for adaptive radiotherapy, adjusting the radiation beam dynamically in response to patient or tumor movement, thereby maximizing dose conformity and protecting healthy tissues. In quality assurance, AI tools can rapidly detect subtle errors in daily imaging and treatment delivery logs, ensuring consistent and high-quality care. Furthermore, AI contributes to predictive modeling, using complex patient data and imaging features to forecast treatment response and potential toxicities, allowing oncologists to personalize treatment plans more effectively. This integration of AI not only addresses the complexity of IGRT by streamlining technical tasks but also helps mitigate the restraint imposed by the shortage of highly skilled staff by automating complex decision-making processes, marking AI as a key enabling technology for the future of Chinese cancer care.
Latest Trends
The China IGRT Market is characterized by several significant and rapidly evolving trends. A major trend is the increasing adoption of MRI-Guided Radiation Therapy (MRI-GRT) systems, which offer superior soft-tissue visualization compared to traditional CT-based IGRT, enabling highly accurate real-time tracking of tumors and organs, particularly in abdominal and thoracic cancers. This advancement is driving the development of personalized and adaptive radiation therapy approaches. Another key trend is the rising interest in Surface-Guided Radiation Therapy (SGRT), which uses external camera systems to monitor patient positioning without requiring additional ionizing radiation, improving workflow efficiency and patient comfort. Furthermore, there is a strong shift toward developing and deploying domestically manufactured IGRT equipment and components, driven by national self-sufficiency goals and efforts to reduce reliance on expensive imported technology. The market is also witnessing the convergence of IGRT with advanced treatment delivery techniques like proton therapy, where image guidance ensures the precise application of particle beams. Finally, the growing implementation of vendor-neutral data platforms and standardized protocols is improving the interoperability and integration of IGRT systems within broader hospital networks across China.